FDA’s has made effective manual procedure and policy for communicating drug approval information. Considering interest of industry and FDA including press an other international counter parts FDA will make drug approval information (Approval Letter) available on CDER’s website.
In the published manual of FDA it is mentioned that, approval and tentative approval letters for original and supplemental drug applications will be made available through CDER’s Web site, generally within three business days of the approval, for the following categories:
1) NDAs and BLAs (Original application, efficacy supplement labeling supplements )
2) ANDAs identified by the Office of Generic Drugs (OGD)
Labeling information of approved ANDA (RLD only), NDA and BLA will be published to CDER’s website within three days of approval of labeling supplement.
You can find manual at below link